Are you over 18 and want to see adult content?
More Annotations
A complete backup of www.bbc.co.uk/sport/football/51638931
Are you over 18 and want to see adult content?
A complete backup of www.goldenstateofmind.com/2020/2/25/21153230/golden-state-warriors-sacramento-kings-draymond-green-dearron-
Are you over 18 and want to see adult content?
A complete backup of timesofindia.indiatimes.com/sports/cricket/australia-in-south-africa/south-africa-vs-australia-2nd-t20i-war
Are you over 18 and want to see adult content?
A complete backup of nikvesti.com/news/politics/180876
Are you over 18 and want to see adult content?
Favourite Annotations
The Close - Actionable Real Estate Strategy from Industry Professionals
Are you over 18 and want to see adult content?
College Connection | Tournaments, Showcases and Camps
Are you over 18 and want to see adult content?
A Trusted Voice For Florida Accident Victims Eric Mausner Law
Are you over 18 and want to see adult content?
Solitaire Paradise - The Best Selection of Free Card Games and Solitaire
Are you over 18 and want to see adult content?
Encontre os serviços de que você precisa no brasil
Are you over 18 and want to see adult content?
Core Facility Management Software | Facility Management System | Idea Elan
Are you over 18 and want to see adult content?
Text
GENE THERAPY NET
Gene Therapy Net is the web resource for patients and professionals interested in gene therapy. The objectives of Gene Therapy Net are to be the information resource for basic and clinical research in gene therapy, cell therapy, and genetic vaccines, and to OVERVIEW OF GENE THERAPY METHODS AND TYPES OF GENE THERAPY The virus enters the cells and inserts the desired gene into the cells’ DNA. The cells grow in the laboratory and are then returned to the patient by injection into a vein. This type of gene therapy is called ex vivo because the cells are treated outside the body. in vivo, which means interior (where genes are changed in cells still inthe body).
BASIC PROCESS OF GENE THERAPY Basic Process of Gene Therapy. Several approaches to gene therapy are being tested, including: - Replacing a mutated gene that causes disease with a healthy copy of the gene. - Inactivating, or “knocking out,” a mutated gene that is functioning improperly. -Introducing a new
GENE THERAPY CLINICAL TRIALS DATABASES The database is a registry of federally and privately supported clinical trials conducted in the United States and around the world. ClinicalTrials.gov gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details. >> Overview of gene therapy trials recently received in the last 30 days. GENE THERAPY CONFERENCES 2021 22 - 25 February 2021. 4th Annual Gene Therapy for Rare Disorders. Boston, MA. 9 - 11 March 2021. 2nd Gene Therapy for Blood Disorders meeting. Online event. 15 - 17 March 2021. International Society for BioProcess Technology 10th Spring Meeting - Viral vectors and vaccines. Norfolk, Virginia.GENE EDITING TOOLS
Gene Editing Tools. Gene editing, or genome editing with engineered nucleases is a type of genetic engineering in which DNA is inserted, deleted or replaced in the genome of an organism using engineered nucleases, or "molecular scissors." These nucleases create site-specific double-strand breaks (DSBs) at desired locations in thegenome.
ZINC FINGER NUCLEASE AS GENE EDITING TOOL Alongside Cas9 and TALEN proteins, ZFN is becoming a prominent tool in the field of genome editing. A zinc finger nuclease is a site-specific endonuclease designed to bind and cleave DNA at specific positions (see figure 1 and video 1). There are two protein domains. The first domain is the DNA binding domain, which consists of eukaryotic ZALMOXIS - GENE THERAPY NET Zalmoxis is a type of advanced therapy medicine called a ‘somatic cell therapy product’. This is a type of medicine containing cells or tissues that have been manipulated so that they can be used to cure, diagnose or prevent a disease. Zalmoxis contains T cells (a type of white blood cell) that have been genetically modified1. IMLYGIC - GENE THERAPY NET Imlygic (talimogene laherparepvec) is a genetically modified herpes virus used to treat melanoma. Imlygic was approved by the FDA at October 27, 2015 and by the EMA at December 17, 2015. It was originally developed by BioVex and continued by Amgen after the GENE THERAPY LEGISLATION IN GERMANY Gene Therapy Legislation in Germany. Clinical trials with medicinal products for human use containing or consisting of GMOs are regulated under the deliberate release framework- Part B of Directive 2001/18. A single submission procedure applies to seek authorization under the clinical trials framework and under the GMO framework (submission toGENE THERAPY NET
Gene Therapy Net is the web resource for patients and professionals interested in gene therapy. The objectives of Gene Therapy Net are to be the information resource for basic and clinical research in gene therapy, cell therapy, and genetic vaccines, and to OVERVIEW OF GENE THERAPY METHODS AND TYPES OF GENE THERAPY The virus enters the cells and inserts the desired gene into the cells’ DNA. The cells grow in the laboratory and are then returned to the patient by injection into a vein. This type of gene therapy is called ex vivo because the cells are treated outside the body. in vivo, which means interior (where genes are changed in cells still inthe body).
BASIC PROCESS OF GENE THERAPY Basic Process of Gene Therapy. Several approaches to gene therapy are being tested, including: - Replacing a mutated gene that causes disease with a healthy copy of the gene. - Inactivating, or “knocking out,” a mutated gene that is functioning improperly. -Introducing a new
GENE THERAPY CLINICAL TRIALS DATABASES The database is a registry of federally and privately supported clinical trials conducted in the United States and around the world. ClinicalTrials.gov gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details. >> Overview of gene therapy trials recently received in the last 30 days. GENE THERAPY CONFERENCES 2021 22 - 25 February 2021. 4th Annual Gene Therapy for Rare Disorders. Boston, MA. 9 - 11 March 2021. 2nd Gene Therapy for Blood Disorders meeting. Online event. 15 - 17 March 2021. International Society for BioProcess Technology 10th Spring Meeting - Viral vectors and vaccines. Norfolk, Virginia.GENE EDITING TOOLS
Gene Editing Tools. Gene editing, or genome editing with engineered nucleases is a type of genetic engineering in which DNA is inserted, deleted or replaced in the genome of an organism using engineered nucleases, or "molecular scissors." These nucleases create site-specific double-strand breaks (DSBs) at desired locations in thegenome.
ZINC FINGER NUCLEASE AS GENE EDITING TOOL Alongside Cas9 and TALEN proteins, ZFN is becoming a prominent tool in the field of genome editing. A zinc finger nuclease is a site-specific endonuclease designed to bind and cleave DNA at specific positions (see figure 1 and video 1). There are two protein domains. The first domain is the DNA binding domain, which consists of eukaryotic ZALMOXIS - GENE THERAPY NET Zalmoxis is a type of advanced therapy medicine called a ‘somatic cell therapy product’. This is a type of medicine containing cells or tissues that have been manipulated so that they can be used to cure, diagnose or prevent a disease. Zalmoxis contains T cells (a type of white blood cell) that have been genetically modified1. IMLYGIC - GENE THERAPY NET Imlygic (talimogene laherparepvec) is a genetically modified herpes virus used to treat melanoma. Imlygic was approved by the FDA at October 27, 2015 and by the EMA at December 17, 2015. It was originally developed by BioVex and continued by Amgen after the GENE THERAPY LEGISLATION IN GERMANY Gene Therapy Legislation in Germany. Clinical trials with medicinal products for human use containing or consisting of GMOs are regulated under the deliberate release framework- Part B of Directive 2001/18. A single submission procedure applies to seek authorization under the clinical trials framework and under the GMO framework (submission to GENE THERAPY TECHNOLOGY EXPLANIED Gene therapy is an experimental treatment that involves introducing genetic material into a person’s cells to fight or prevent disease. Researchers are studying gene therapy for a number of diseases, such as severe combined immuno-deficiencies, hemophilia, Parkinson's disease, cancer and even HIV, through a number of different approaches (see video: 'Gene Therapy a new tool to cure human GENE THERAPY CLINICAL TRIALS DATABASES The database is a registry of federally and privately supported clinical trials conducted in the United States and around the world. ClinicalTrials.gov gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details. >> Overview of gene therapy trials recently received in the last 30 days. DISEASES TREATED BY GENE THERAPY Diseases Treated by Gene Therapy. Gene Therapy was initially meant to introduce genes straight into human cells, focusing on diseases caused by single-gene defects, such as cystic fibrosis, hemophilia, muscular dystrophy (see video 2) and sickle cell anemia (see also Wiley database on indications addressed by gene therapy clinical trials ). WWW.GENETHERAPYNET.COM Selection of Gene Therapy news items published on Mon, 7 June 2021, 18:00. Go back to archive list. Previous day | Next day. Bluebird cleared by FDA to resume studies of sickle cell gene therapy ZALMOXIS - GENE THERAPY NET Zalmoxis is a type of advanced therapy medicine called a ‘somatic cell therapy product’. This is a type of medicine containing cells or tissues that have been manipulated so that they can be used to cure, diagnose or prevent a disease. Zalmoxis contains T cells (a type of white blood cell) that have been genetically modified1. IMLYGIC - GENE THERAPY NET Imlygic (talimogene laherparepvec) is a genetically modified herpes virus used to treat melanoma. Imlygic was approved by the FDA at October 27, 2015 and by the EMA at December 17, 2015. It was originally developed by BioVex and continued by Amgen after the GENE THERAPY AND MOLECULAR BIOLOGY The scope of Gene Therapy and Molecular Biology is to promote interaction between researchers in the fields of Gene Therapy and Molecular Biology providing rapid publication of review articles and research papers. Articles, both invited and submitted, review or report novel findings of importance to a general audience in gene therapy, molecular medicine, gene discovery, and molecular biology ONCORINE - GENE THERAPY NET Shanghai Sunway Biotech Co. Ltd. announced in November 2005 that the Chinese State Food and Drug Administration has approved Oncorine (H101), an oncolytic adenovirus, to be used in combination with chemotherapy as a treatment for patients with late stage refractory nasopharyngeal cancer. This marks the first oncolytic viral therapy approved by any regulatory agency in the world and this is the ZYNTEGLO - GENE THERAPY NET Zynteglo is a medicine used to treat a blood disorder known as beta thalassaemia in patients 12 years and older who require regular blood transfusions. People with this genetic condition cannot make enough beta-globin, a component of haemoglobin, the protein in red blood cells that carries oxygen ar GENE THERAPY MULTIPLE CHOICE QUIZ Gene therapy is becoming a major area in medical research. How much do you know about gene therapy? Take the quiz and test your knowledge! Each quiz contains 10 questions about gene therapy. The correct answer is given after each submitted answer. Good luck! Download here the complete quiz, including questions, answers and explanation.GENE THERAPY NET
Gene Therapy Net is the web resource for patients and professionals interested in gene therapy.The objectives of Gene Therapy Net are to be the information resource for basic and clinical research in gene therapy, cell therapy, and genetic vaccines, and to serve as a network in the exchange of information and news related to above areas. BREAKING GENE THERAPY NEWS Bluebird cleared by FDA to resume studies of sickle cell gene therapy - BioPharma Dive Jun 7, 2021 | 17:59 pm. Bluebird cleared by FDA to resume studies of sickle cell gene therapy BioPharma DiveFDA lets bluebird resume trials for sickle cell gene therapy after cancer scare, but big questions linger over field Endpoints NewsBluebird's Zynteglo trials set to resume, putting gene therapy back on BASIC PROCESS OF GENE THERAPY Basic Process of Gene Therapy. Several approaches to gene therapy are being tested, including: - Replacing a mutated gene that causes disease with a healthy copy of the gene. - Inactivating, or “knocking out,” a mutated gene that is functioning improperly. -Introducing a new
GENE THERAPY CLINICAL TRIALS DATABASES The database is a registry of federally and privately supported clinical trials conducted in the United States and around the world. ClinicalTrials.gov gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details. >> Overview of gene therapy trials recently received in the last 30 days. DISEASES TREATED BY GENE THERAPY Diseases Treated by Gene Therapy. Gene Therapy was initially meant to introduce genes straight into human cells, focusing on diseases caused by single-gene defects, such as cystic fibrosis, hemophilia, muscular dystrophy (see video 2) and sickle cell anemia (see also Wiley database on indications addressed by gene therapy clinical trials ).GENE EDITING TOOLS
Gene Editing Tools. Gene editing, or genome editing with engineered nucleases is a type of genetic engineering in which DNA is inserted, deleted or replaced in the genome of an organism using engineered nucleases, or "molecular scissors." These nucleases create site-specific double-strand breaks (DSBs) at desired locations in thegenome.
GENE THERAPY CONFERENCES 2021 22 - 25 February 2021. 4th Annual Gene Therapy for Rare Disorders. Boston, MA. 9 - 11 March 2021. 2nd Gene Therapy for Blood Disorders meeting. Online event. 15 - 17 March 2021. International Society for BioProcess Technology 10th Spring Meeting - Viral vectors and vaccines. Norfolk, Virginia. ZINC FINGER NUCLEASE AS GENE EDITING TOOL Alongside Cas9 and TALEN proteins, ZFN is becoming a prominent tool in the field of genome editing. A zinc finger nuclease is a site-specific endonuclease designed to bind and cleave DNA at specific positions (see figure 1 and video 1). There are two protein domains. The first domain is the DNA binding domain, which consists of eukaryotic ZALMOXIS - GENE THERAPY NET Zalmoxis is a type of advanced therapy medicine called a ‘somatic cell therapy product’. This is a type of medicine containing cells or tissues that have been manipulated so that they can be used to cure, diagnose or prevent a disease. Zalmoxis contains T cells (a type of white blood cell) that have been genetically modified1. IMLYGIC - GENE THERAPY NET Imlygic (talimogene laherparepvec) is a genetically modified herpes virus used to treat melanoma. Imlygic was approved by the FDA at October 27, 2015 and by the EMA at December 17, 2015. It was originally developed by BioVex and continued by Amgen after theGENE THERAPY NET
Gene Therapy Net is the web resource for patients and professionals interested in gene therapy.The objectives of Gene Therapy Net are to be the information resource for basic and clinical research in gene therapy, cell therapy, and genetic vaccines, and to serve as a network in the exchange of information and news related to above areas. BREAKING GENE THERAPY NEWS Bluebird cleared by FDA to resume studies of sickle cell gene therapy - BioPharma Dive Jun 7, 2021 | 17:59 pm. Bluebird cleared by FDA to resume studies of sickle cell gene therapy BioPharma DiveFDA lets bluebird resume trials for sickle cell gene therapy after cancer scare, but big questions linger over field Endpoints NewsBluebird's Zynteglo trials set to resume, putting gene therapy back on BASIC PROCESS OF GENE THERAPY Basic Process of Gene Therapy. Several approaches to gene therapy are being tested, including: - Replacing a mutated gene that causes disease with a healthy copy of the gene. - Inactivating, or “knocking out,” a mutated gene that is functioning improperly. -Introducing a new
GENE THERAPY CLINICAL TRIALS DATABASES The database is a registry of federally and privately supported clinical trials conducted in the United States and around the world. ClinicalTrials.gov gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details. >> Overview of gene therapy trials recently received in the last 30 days. DISEASES TREATED BY GENE THERAPY Diseases Treated by Gene Therapy. Gene Therapy was initially meant to introduce genes straight into human cells, focusing on diseases caused by single-gene defects, such as cystic fibrosis, hemophilia, muscular dystrophy (see video 2) and sickle cell anemia (see also Wiley database on indications addressed by gene therapy clinical trials ).GENE EDITING TOOLS
Gene Editing Tools. Gene editing, or genome editing with engineered nucleases is a type of genetic engineering in which DNA is inserted, deleted or replaced in the genome of an organism using engineered nucleases, or "molecular scissors." These nucleases create site-specific double-strand breaks (DSBs) at desired locations in thegenome.
GENE THERAPY CONFERENCES 2021 22 - 25 February 2021. 4th Annual Gene Therapy for Rare Disorders. Boston, MA. 9 - 11 March 2021. 2nd Gene Therapy for Blood Disorders meeting. Online event. 15 - 17 March 2021. International Society for BioProcess Technology 10th Spring Meeting - Viral vectors and vaccines. Norfolk, Virginia. ZINC FINGER NUCLEASE AS GENE EDITING TOOL Alongside Cas9 and TALEN proteins, ZFN is becoming a prominent tool in the field of genome editing. A zinc finger nuclease is a site-specific endonuclease designed to bind and cleave DNA at specific positions (see figure 1 and video 1). There are two protein domains. The first domain is the DNA binding domain, which consists of eukaryotic ZALMOXIS - GENE THERAPY NET Zalmoxis is a type of advanced therapy medicine called a ‘somatic cell therapy product’. This is a type of medicine containing cells or tissues that have been manipulated so that they can be used to cure, diagnose or prevent a disease. Zalmoxis contains T cells (a type of white blood cell) that have been genetically modified1. IMLYGIC - GENE THERAPY NET Imlygic (talimogene laherparepvec) is a genetically modified herpes virus used to treat melanoma. Imlygic was approved by the FDA at October 27, 2015 and by the EMA at December 17, 2015. It was originally developed by BioVex and continued by Amgen after the BREAKING GENE THERAPY NEWS Bluebird cleared by FDA to resume studies of sickle cell gene therapy - BioPharma Dive Jun 7, 2021 | 17:59 pm. Bluebird cleared by FDA to resume studies of sickle cell gene therapy BioPharma DiveFDA lets bluebird resume trials for sickle cell gene therapy after cancer scare, but big questions linger over field Endpoints NewsBluebird's Zynteglo trials set to resume, putting gene therapy back on OVERVIEW OF GENE THERAPY METHODS AND TYPES OF GENE THERAPY The virus enters the cells and inserts the desired gene into the cells’ DNA. The cells grow in the laboratory and are then returned to the patient by injection into a vein. This type of gene therapy is called ex vivo because the cells are treated outside the body. in vivo, which means interior (where genes are changed in cells still inthe body).
GENE THERAPY TECHNOLOGY EXPLANIED Gene therapy is an experimental treatment that involves introducing genetic material into a person’s cells to fight or prevent disease. Researchers are studying gene therapy for a number of diseases, such as severe combined immuno-deficiencies, hemophilia, Parkinson's disease, cancer and even HIV, through a number of different approaches (see video: 'Gene Therapy a new tool to cure human GENE THERAPY CLINICAL TRIALS DATABASES The database is a registry of federally and privately supported clinical trials conducted in the United States and around the world. ClinicalTrials.gov gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details. >> Overview of gene therapy trials recently received in the last 30 days. ZALMOXIS - GENE THERAPY NET Zalmoxis is a type of advanced therapy medicine called a ‘somatic cell therapy product’. This is a type of medicine containing cells or tissues that have been manipulated so that they can be used to cure, diagnose or prevent a disease. Zalmoxis contains T cells (a type of white blood cell) that have been genetically modified1. ZYNTEGLO - GENE THERAPY NET Zynteglo is a medicine used to treat a blood disorder known as beta thalassaemia in patients 12 years and older who require regular blood transfusions. People with this genetic condition cannot make enough beta-globin, a component of haemoglobin, the protein in red blood cells that carries oxygen ar GENE THERAPY VIRAL VECTORS EXPLAINED Viruses can usually infect more than one type of cell. Thus, when viral vectors are used to carry genes into the body, they might infect healthy cells as well as cancer cells. Another danger is that the new gene might be inserted in the wrong location in the DNA, possibly causing harmful mutations to CRISPR-CAS9 SYSTEM AS GENE EDITING TOOL CRISPR/Cas9 genome editing is carried out with a Type II CRISPR system. Cas9 is an enzyme (nuclease) that cuts DNA, and CRISPR is a collection of DNA sequences that tells Cas9 exactly where to cut. A guide RNA is required to feed Cas9 the right sequence, where to cut and paste bits of DNA sequence into the genome wherever you want. GENE THERAPY MULTIPLE CHOICE QUIZ Gene therapy is becoming a major area in medical research. How much do you know about gene therapy? Take the quiz and test your knowledge! Each quiz contains 10 questions about gene therapy. The correct answer is given after each submitted answer. Good luck! Download here the complete quiz, including questions, answers and explanation. POINTS TO CONSIDER FOR HUMAN GENE THERAPY AND PRODUCT 6 Points to Consider for Human Gene Therapy and Product Quality Control State Food and Drug Administration of China This document by Shenzhen SiBiono GeneTech Co.,Ltd.and the National Institute for the Control of Pharmaceutical and* Home
* Breaking News
* Patient Information* Conferences
* Publications
* Viral Vectors
* Clinical Trials
* Books
* Jobs
* Quiz
MAIN MENU
* What is Gene Therapy* Gene Therapy News
* Societies
* Companies
* Regulatory Affairs * Research Institutes * Clinical Trial Databases* Literature
* Discussion Forum
* Newsletter
* Contact
LOGIN
Registration is free and allows users complete access to all sections of the site, including archived news items. You also receive our freenewsletter.
Username
Password
Remember Me
Log in
* Create an account
* Forgot your username? * Forgot your password?NEW CLINICAL TRIALS
* Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic Neuropathy Associated With ND4 Mutations Jun 3, 2021 | 18:00 pm * Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy Jun 2, 2021 | 18:00 pm More clinical trialsScience Jobs
ADVERTISE ON THIS SITE? Advertising opportunities on Gene Therapy Net include standard size banners as well as text ads. Click here for more information aboutadvertising.
------------------------- You can also make a donation by PayPal and support the Gene TherapyNet website.
MOST POPULAR ITEMS
* Types of Gene Therapy * Breaking Gene Therapy News * Diseases Treated by Gene Therapy * Adeno-Associated Viral Vectors * Retroviral VectorsWHO'S ONLINE
We have 173 guests and no members onlineSTATISTICS
* Users 4846
* Articles 629
* Articles View Hits 12579492 WELCOME TO GENE THERAPY NET GENE THERAPY NET is the web resource for patients and professionals interested in gene therapy . The objectives of Gene Therapy Net are to be the information resource for basic and clinical research in gene therapy, cell therapy, and genetic vaccines, and to serve as a network in the exchange of information and news related to above areas. In addition, Gene Therapy Net provides an overview for sponsors and researchers of the different international regulations and guidelines associated with clinical gene therapy trials . For resources pertaining to regenerative cell therapy and clinical treatment, check out R3 StemCell .
DECADES AFTER A TRAGIC FAILURE, GENE THERAPY SUCCESSFULLY TREATS ARARE LIVER DISEASE
_Posted on: 19 May 2021, source: Science_ Twenty-two years ago, one of scientists’ first attempts at gene therapy ended in tragedy when a young man died. The story of Jesse Gelsinger, who had a rare liver disorder, became a textbook example of irresponsible medical research. For years, the case hobbled efforts to treat diseases by adding new DNA to a sick person’s cells. Now, a fresh effort to cure Gelsinger’s disease is bearing fruit, in the latest sign of the field’s resurgence.fShare
Share
Register to read more ... NEW GENE THERAPY RESTORES DYSTROPHIN PROTEIN IN PATIENTS WITH DUCHENNEMUSCULAR DYSTROPHY
_Posted on: 4 May 2021, source: News-Medical.net_ UT Southwestern scientists successfully employed a new type of gene therapy to treat mice with Duchenne muscular dystrophy (DMD), uniquely utilizing CRISPR-Cas9-based tools to restore a large section of the dystrophin protein that is missing in many DMD patients. The approach, described online today in the journal Science Advances, could lead to a treatment for DMD and inform the treatment of other inheriteddiseases.
fShare
Share
Register to read more ... NEW APPROACH TO CAR T GENE THERAPY YIELDS EFFICIENT AND LONGER-LASTING RESPONSE AGAINST HIV _Posted on: 5 April 2021, source: News-Medical.net_ A UCLA research team has shown that using a truncated form of the CD4 molecule as part of a gene therapy to combat HIV yielded superior and longer-lasting results in mouse models than previous similar therapies using the CD4 molecule. This new approach to CAR T gene therapy -- a type of immunotherapy that involves genetically engineering the body's own blood-forming stem cells to create HIV-fighting T cells -- has the potential to not only destroy HIV-infected cells but to create "memory cells" that could provide lifelong protection from infection with the virus that causes AIDS.fShare
Share
Register to read more ... EMA LAUNCHES SAFETY REVIEW AFTER GENE THERAPY TRIAL PATIENT DEVELOPSBLOOD CANCER
_Posted on: 13 March 2021, source: BioSpace_ The European Medicines Agency (EMA) has launched a safety review of bluebird bio’s thalassaemia drug Zynteglo, a conditionally licensed gene therapy in Europe. This review comes after researchers identified an acute myeloid leukaemia (AML) case in a patient who received bb1111 (LentiGlobin), an investigational gene therapy for sickle cell disease (SCD), in a Phase I/II study. This therapy relies on the same viral vector found in Zynteglo which delivers a gene into cells.fShare
Share
Register to read more ... GENE THERAPY TRIALS FOR SICKLE CELL DISEASE HALTED AFTER TWO PATIENTSDEVELOP CANCER
_Posted on: 22 February 2021, source: Science_ A company has stopped its clinical studies of a promising gene therapy for the blood disorder sickle cell disease after two people who participated developed leukemia-like cancer. Bluebird bio is now investigating whether a virus it uses to deliver a therapeutic gene caused the cancers, reviving old concerns about the risks of this approach. It’s also possible the cancers stemmed from chemotherapy the patients received to prepare their bodies for the gene’s delivery. “This is really a sad development whatever the cause,” says Donald Kohn of the University of California, Los Angeles, who has led gene therapy trials for sickle cell and other diseases.fShare
Share
Register to read more ... MANUFACTURING CONSIDERATIONS FOR LICENSED AND INVESTIGATIONAL CELLULAR AND GENE THERAPY PRODUCTS DURING COVID-19 PUBLIC HEALTH EMERGENCY _Posted on: 24 January 2021, source: FDA_ FDA is issuing this guidance to provide manufacturers of licensed and investigational cellular therapy and gene therapy (CGT) products with risk-based recommendations to minimize potential transmission of the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This guidance is intended to supplement the recommendations to drug and biological product manufacturers provided in FDA’s “Good Manufacturing Practice Considerations for Responding to COVID-19 Infection in Employees in Drug and Biological Products Manufacturing; Guidance for Industry” issued in June 2020 (Ref. 1) (June 2020 GMP Guidance). The recommendations in this guidance specifically consider the source material (cells and/or tissues) recovered from donors and how the CGT product will be manufactured (e.g., cell expansion in culture, viral reduction steps,formulation).
fShare
Share
Register to read more ... LIVER TUMOR IN GENE THERAPY RECIPIENT RAISES CONCERNS ABOUT VIRUS WIDELY USED IN TREATMENT _Posted on: 23 December 2020, source: Science_ It’s troubling news that gene therapy researchers have long anticipated: A hemophilia patient injected with a virus carrying a therapeutic gene in a clinical trial has developed a liver tumor. The U.S. Food and Drug Administration (FDA) has halted the associated clinical trials, and uniQure, the Dutch firm behind the studies, is now investigating whether the virus itself caused the cancer. Gene therapy experts say that’s unlikely. The patient had underlying conditions that predisposed him to liver cancer. Still, scientists say it’s crucial to rule out any role for adeno-associated virus (AAV), the viral delivery system, or vector, that is used in hundreds of other gene therapy trials. “Everyone will want to know what happened,” says physician-scientist David Lillicrap of Queen’s University, a hemophilia researcher who was not involved with theuniQure study.
fShare
Share
Register to read more ...GENE THERAPY NEWS
* Cancer Vaccines Market and Cancer Gene Therapy Market Size 2021 -GlobeNewswire
Jun 5, 2021 | 16:51 pm * Bedford biotech’s gene therapy improves sight for 11 patients with a rare genetic retina disorder - The Dallas Morning News Jun 4, 2021 | 13:46 pm * Orchard abandons promising gene therapy for rare immune disorder -BioPharma Dive
Jun 3, 2021 | 18:44 pm * ASGCT 2021: The Gene Therapy Show Must Go On - Genetic Engineering & Biotechnology News Jun 3, 2021 | 08:55 am * Newer methods may boost gene therapy's use for more diseases -Associated Press
Jun 2, 2021 | 07:08 am Read more breaking news.UPCOMING EVENTS
View here more conferences GENE THERAPY LITERATURE Scroll through the latest articles in gene therapy scientific journals . ------------------------- You can buy a unique research paper online on gene therapy topics here.
RECENT MODIFIED ITEMS * Gene Therapy Conferences 2021* Selected jobs
* Gene therapy trials for sickle cell disease halted after two patients develop cancer * EMA Launches Safety Review After Gene Therapy Trial Patient Develops Blood Cancer * New approach to CAR T gene therapy yields efficient and longer-lasting response against HIV 2021 Gene Therapy Net. Contact Us|
Privacy Policy | About Us| Sitemap
Bookmark | Homepage | Link | cprcertificationcourses^ Back to Top
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0